Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Adenocarcinoma (1)
- Animals (1)
- Antineoplastic Agents (1)
- Castration-Resistant (1)
- Cell Line (1)
-
- Cell Line, Tumor (1)
- Department of Cancer Biology (1)
- Flow Cytometry (1)
- Fluorescence (1)
- Humans (1)
- Immunoblotting (1)
- Kimmel Cancer Center (1)
- Male (1)
- Mice (1)
- Microscopy (1)
- Microscopy, Fluorescence (1)
- Models (1)
- Models, Molecular (1)
- Molecular (1)
- Oligonucleotide Array Sequence Analysis (1)
- Prostatic Neoplasms (1)
- Prostatic Neoplasms, Castration-Resistant (1)
- Taxoids (1)
- Thomas Jefferson University; adult; aged; animal experiment; animal model; Article; cancer growth; cancer recurrence; cancer staging; controlled study; disease association; down regulation; epigenetics; gene dosage; gene locus; gene overexpression; gene silencing; human; human cell; human tissue; major clinical study; male; mouse; nonhuman; prediction; prostate cancer (1)
- Transcriptome (1)
- Tumor (1)
- Xenograft Model Antitumor Assays (1)
Articles 1 - 2 of 2
Full-Text Articles in Entire DC Network
Deregulation Of Mir-34b/Sox2 Predicts Prostate Cancer Progression., Irene Forno, Stefano Ferrero, Maria Veronica Russo, Giacomo Gazzano, Sara Giangiobbe, Emanuele Montanari, Alberto Del Nero, Bernardo Rocco, Giancarlo Albo, Lucia R Languino, Dario C Altieri, Valentina Vaira, Silvano Bosari
Deregulation Of Mir-34b/Sox2 Predicts Prostate Cancer Progression., Irene Forno, Stefano Ferrero, Maria Veronica Russo, Giacomo Gazzano, Sara Giangiobbe, Emanuele Montanari, Alberto Del Nero, Bernardo Rocco, Giancarlo Albo, Lucia R Languino, Dario C Altieri, Valentina Vaira, Silvano Bosari
Department of Cancer Biology Faculty Papers
Most men diagnosed with prostate cancer will have an indolent and curable disease, whereas approximately 15% of these patients will rapidly progress to a castrate-resistant and metastatic stage with high morbidity and mortality. Therefore, the identification of molecular signature(s) that detect men at risk of progressing disease remains a pressing and still unmet need for these patients. Here, we used an integrated discovery platform combining prostate cancer cell lines, a Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model and clinically-annotated human tissue samples to identify loss of expression of microRNA-34b as consistently associated with prostate cancer relapse. Mechanistically, this was …
Novel Actions Of Next-Generation Taxanes Benefit Advanced Stages Of Prostate Cancer., Renée De Leeuw, Lisa D. Berman-Booty, Matthew J. Schiewer, Stephen J Ciment, Robert Den, Adam P. Dicker, William Kelly, Edouard J. Trabulsi, Costas D. Lallas, Leonard G. Gomella, Karen E. Knudsen
Novel Actions Of Next-Generation Taxanes Benefit Advanced Stages Of Prostate Cancer., Renée De Leeuw, Lisa D. Berman-Booty, Matthew J. Schiewer, Stephen J Ciment, Robert Den, Adam P. Dicker, William Kelly, Edouard J. Trabulsi, Costas D. Lallas, Leonard G. Gomella, Karen E. Knudsen
Department of Cancer Biology Faculty Papers
PURPOSE: To improve the outcomes of patients with castration-resistant prostate cancer (CRPC), there is an urgent need for more effective therapies and approaches that individualize specific treatments for patients with CRPC. These studies compared the novel taxane cabazitaxel with the previous generation docetaxel, and aimed to determine which tumors are most likely to respond.
EXPERIMENTAL DESIGN: Cabazitaxel and docetaxel were compared via in vitro modeling to determine the molecular mechanism, biochemical and cell biologic impact, and cell proliferation, which was further assessed ex vivo in human tumor explants. Isogenic pairs of RB knockdown and control cells were interrogated in vitro …